Pipeline & Show cases

Accelerating
Toward the Clinic.

Our lead AI-designed candidates are now being tested in vivo. We are advancing our top programs toward clinical trials.

Pipeline & Show cases

We are generating the next pharmaceutical using our pipeline.

Target

HER2

Experimental Kd

0.0 nM

  1. Design the LeadCompleted
  2. Optimize the LeadCompleted
  3. In Vitro Binding AssayCompleted
  4. In Vivo ValidationIn Progress
  5. Translational & Regulatory StepUpcoming
  6. Clinical TrialUpcoming

Target

TROP2

Experimental Kd

0.0 nM

  1. Design the LeadCompleted
  2. Optimize the LeadCompleted
  3. In Vitro Binding AssayCompleted
  4. In Vivo ValidationIn Progress
  5. Translational & Regulatory StepUpcoming
  6. Clinical TrialUpcoming

Target

CD38

Experimental Kd

0.0 nM

  1. Design the LeadCompleted
  2. Optimize the LeadCompleted
  3. In Vitro Binding AssayCompleted
  4. In Vivo ValidationIn Progress
  5. Translational & Regulatory StepUpcoming
  6. Clinical TrialUpcoming

Target

PD-L1

Experimental Kd

0 nM

  1. Design the LeadCompleted
  2. Optimize the LeadCompleted
  3. In Vitro Binding AssayCompleted
  4. In Vivo ValidationIn Progress
  5. Translational & Regulatory StepUpcoming
  6. Clinical TrialUpcoming

The journey

From the first designed lead to the clinic — six stages, one intelligence layer.

  1. Design the Lead

    Completed · Q1 2026

  2. Optimize the Lead

    Completed · Q1 2026

  3. In Vitro Binding Assay

    Completed · Q1 2026

  4. In Vivo Validation

    In Progress · Q2 2026

  5. Translational & Regulatory Step

    Upcoming · Q3 2026

  6. Clinical Trial

    Upcoming · Q4 2026

ProgramsHER2 2.1 nMTROP2 8.5 nMCD38 19.5 nMPD-L1 45 nM

More programs: Coming Soon…

Contact

Bring us a target.

Move from disease biology to a collaborative end-to-end program—from target discovery through lead generation—combining Epitorix intelligence with the scientists guiding the development path.

Target discoveryEnd-to-end

/Contact

Start the Conversation That Moves You Forward